Ixense (apomorphine)
- Region
- 🇪🇺 EU
- Active substance
- apomorphine
- Company
- Takeda Europe R Centre Ltd.
- Status
- Withdrawn
- Therapeutic area
- Erectile Dysfunction
- EU approval
- Mon 28 May 2001
- Application
- EMEA/H/C/000328
- ATC
- G04BE
- Official record
- www.ema.europa.eu
Indication
Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.In order for Ixense to be effective, sexual stimulation is required.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Uprima Withdrawn · Abbott Laboratories Ltd.
- 🇪🇺 Taluvian Withdrawn · Abbott S.r.l.
Follow Ixense
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.